- Home
- HAPN vs AUPH Comparison
HAPN vs AUPH Comparison
Compare HAPN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$15.35
Company Overview
Basic Information| Metric | HAPN | AUPH |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | HAPN | AUPH |
|---|---|---|
| Price | $18.06 | $15.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | ★ 1.6M | 1.6M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | N/A | $15.74 |
| P/E Ratio | ★ N/A | $60.96 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $17.93 | $8.80 |
| 52 Week High | $21.21 | $19.25 |
Technical Indicators
Market Signals| Indicator | HAPN | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 33.38 | 43.01 |
| Support Level | N/A | $14.60 |
| Resistance Level | $20.94 | $16.38 |
| Average True Range (ATR) | 0.68 | 0.57 |
| MACD | -0.17 | -0.11 |
| Stochastic Oscillator | 6.22 | 21.01 |
Price Performance
Historical Comparison HAPN
AUPH
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.